Earlier this summer, I wrote I had a suspicion: Boston was quietly becoming one of the most important cities in the long term.

Not because it was competing with Switzerland for luxury longevity clinics or Dubai on medical tourism. My argument was that Boston has something potentially even more valuable: the concentration of scientists, physicians, hospitals, biotech companies, and capital that is needed to actually test whether the things being sold work for longevity.

since then i have been watching boston longevity week take shape.

What started as an interesting collection of events has turned into an 11-day gathering of researchers, physicians, pharmaceutical executives, biotech founders, investors and entrepreneurs in Boston this October. There are conferences dedicated to Biomarkers of aging and Brain Aging, an AI hackathon, an investor pitch night featuring over 30 venture firms, and a healthy aging symposium.

Then I reached the closing event of the calendar: the Translational Longevity Summit.

That word caught my attention.

Translational.

Not anti-aging. No reversal of age. Not biohacking.

Translation.

So I set out to find out what it really meant and, more interestingly, who was behind it.

That's when I realized that longevity doesn't have a novelty problem. There aren't any regulatory issues either (well, that depends on who you talk to).

Longevity has translation problems

remember the movie lost in Translation? This is a longevity industry right now.

If you've spent any time in this space, you know that we don't suffer from a lack of things that promise to help us. live longer or be healthier.

Peptides. Stem cells. Exosomes. NAD. red light. Hyperbaric oxygen. plasma exchange. Wearable items. biological age test. Supplement. Hormones. Diagnosis. Science is moving incredibly fast, and entrepreneurs are commercializing it just as fast.

But discovery is not the same as therapy.

Something may look promising in the laboratory and it may still be years before it becomes an intervention used by a physician. A technology may exist without physicians understanding how to implement it. A biomarker can be measured without the industry agreeing on what that measurement actually means. And consumers may get excited about an intervention much earlier Clinical evidence bears out.

This is the gap: between what we can discover and what we can responsibly deliver. And I think there's a huge business opportunity right in the middle of this.

Looking at the summit, I found two people whose careers were not what I expected.

Joseph Krieger, president of Boston BioLife, studied biochemistry before going into the medical-device industry. Rather than spend his career inventing a therapy, he eventually created an education business focused on helping medical professionals understand emerging technologies and how they can actually be applied in practice.

Then there's Bernard Siegel.

Siegel spent decades as a courtroom lawyer in Miami, and his foray into regenerative medicine began with one of the strangest stories I encountered while researching this industry.

In 2002, Cloned announced that it had produced the world's first cloned human child, a girl it called Eve. The company did not provide any independent evidence.

Seagal went to court seeking the appointment of a guardian for the alleged child.

Suddenly, a Miami lawyer was at the center of an international debate over human cloning. What could have been a quaint footnote in his legal career instead helped redirect it. Siegel became involved in stem-cell advocacy, founding the HealthSpan Action Coalition and the organization now known as the Regenerative Medicine Foundation, and creating the World Stem Cell Summit, bringing together scientists, physicians, industry, regulators, investors, and patient advocates.

These are two very different career paths, but the more I looked into them, the more I saw what they had in common.

measuring scientific breakthroughs

The primary contribution of any human being was not to discover a molecule or invent the next miracle cure. He made connections around science. and suddenly the words translational Made a lot more sense.

Entrepreneurs love innovation. We are ready to look for the next product, the next technology, the next breakthrough.

But some of the greatest businesses are built after success. They solve everything that prevents an innovation from happening useful at scale.

Think about how much happens between a scientific discovery and it actually benefiting patients.

The research should be repeated. Results have to be measured. Security has to be established. Clinicians must understand the intervention. Protocol will have to be developed. Must navigate regulatory requirements. Patients will have to be identified. Data has to be collected. Results need to be tracked. In some cases, entirely new payment models will have to be explored.

Someone has to connect those worlds.

That is the entrepreneurship area.

And this may be where founders are looking in the wrong direction.

Building roads to longevity

Sexy occasion is another successful therapy. Less attractive opportunities are clinical data infrastructure, physician education, biomarker standardization, compliance platforms, outcome tracking, patient identification, evidence validation and reliable market.

Those things aren't as exciting to talk about at a cocktail party as reversing your biological age.

They can also become very big businesses.

Longevity already has extraordinary scientists. It has ambitious founders. There is huge interest from consumers in this. In this, investors are looking for the next breakthrough.

It does not yet have a mature system for determining which discoveries should move forward, how fast they should move forward, how physicians should use them, who should receive them and whether they actually improve outcomes once they reach patients.

This is not a marketing problem. this is a Translation crisis.

Which brings me back to the question I asked over the summer: Why Boston?

Maybe the answer has less to do with declaring a new “longevity capital” and more to do with what happens when different pieces of an emerging industry start colliding in the same place.

boston longevity week The calendar covers anti-aging drug discovery, biomarkers, AI, biotech investments, brain aging, healthy aging and translational longevity.

This is important because longevity is not really an industry.

It sits somewhere between biotechnology, pharmaceuticals, medicine, wellness, diagnostics, data, consumer health and healthcare policy. And those worlds don't move at the same pace or even speak the same language.

A consumer can hear about the interference on the podcast tomorrow. A startup can start selling it from next month. A scientist may say that the evidence is not mature. A doctor may not know what to tell the patient about it. And a regulator may classify it differently from the entrepreneur selling it.

That's friction. And entrepreneurs should pay great attention to friction.

One question I keep hearing about health and longevity is: What will happen next?

What's the next peptide? Next diagnosis? Next device? Next molecule? The next biohack?

Maybe we are asking the wrong question.

Perhaps we should ask: What's stopping what we already have from becoming reliable, scalable, and medically useful?

Some founders will almost certainly create billions of dollars worth of medical sciences and technologies. we need them.

But I suspect that others will create billion-dollar companies by solving everything that happens between invention and impact.

That's what made the difference for me was researching Boston Longevity Week.

I started by looking at where the longevity industry was converging. Then I started to see people putting different parts of it together. and i've seen a lot big opportunity.

Perhaps longevity doesn't need another miracle product so much as it needs a better way to take good science into the real world.

Longevity The gold rush doesn't need more people selling picks and shovels. People are needed to build roads.

Earlier this summer, I wrote I had a suspicion: Boston was quietly becoming one of the most important cities in the long term.

Not because it was competing with Switzerland for luxury longevity clinics or Dubai for medical tourism. My argument was that Boston has something potentially even more valuable: the concentration of scientists, physicians, hospitals, biotech companies, and capital that is needed to actually test whether the things being sold work for longevity.

since then i have been watching boston longevity week take shape.